Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.

Autor: Hammer, C¹, Stepniak, B¹, Schneider, A², Papiol, S³, Tantra, M³, Begemann, M¹, Sirén, A-L⁴, Pardo, L A⁵, Sperling, S¹, Mohd Jofrry, S¹, Gurvich, A¹, Jensen, N¹, Ostmeier, K¹, Lühder, F⁶, Probst, C⁷, Martens, H⁸, Gillis, M⁹, Saher, G¹⁰, Assogna, F¹¹, Spalletta, G¹¹

Publikováno v: Molecular Psychiatry. Oct2014, Vol. 19 Issue 10, p1143-1149. 7p.

Autism beyond diagnostic categories: Characterization of autistic phenotypes in schizophrenia

Autor: Kästner, A., Begemann, M., Michel, T., Everts, S., Stepniak, B., Bach, C., Poustka, L., Becker, J., Banaschewski, T., Dose, M., Ehrenreich, H.

Publikováno v: Kästner, A, Begemann, M, Michel, T M, Everts, S, Stepniak, B, Bach, C, Poustka, L, Becker, J, Banaschewski, T, Dose, M & Ehrenreich, H 2015, ' Autism beyond diagnostic categories: Characterization of autistic phenotypes in schizophrenia ', BMC Psychiatry, vol. 15, no. 1, 115 . https://doi.org/10.1186/s12888-015-0494-x
BMC Psychiatry

Background Behavioral phenotypical continua from health to disease suggest common underlying mechanisms with quantitative rather than qualitative differences. Until recently, autism spectrum disorders and schizophrenia were considered distinct nosolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bb0d08bf5c645c45effa53f52487392a
https://findresearcher.sdu.dk:8443/ws/files/129582912/Autism_beyond_diagnostic_categories_Characterization_of_autistic_phenotypes_in_schizophrenia.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke.

Autor: Arlt FA; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany. friederike-antonia.arlt@charite.de.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. friederike-antonia.arlt@charite.de., Sperber PS; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany. pia.sperber@charite.de.; Experimental and Clinical Research Center, a cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. pia.sperber@charite.de.; NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany. pia.sperber@charite.de.; German Center for Cardiovascular Diseases (DZHK), Partner Site Berlin, Berlin, Germany. pia.sperber@charite.de., von Rennenberg R; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany., Gebert P; Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany., Teegen B; Clinical Immunological Laboratory Prof. Stöcker, Groß Grönau, Germany., Georgakis MK; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany., Fang R; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany., Dewenter A; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany., Görtler M; Department of Neurology, University Hospital, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.; German Center for Neurodegenerative Diseases (DZNE) Magdeburg, Magdeburg, Germany., Petzold GC; Department of Vascular Neurology, University Hospital Bonn, Bonn, Germany.; German Center for Neurodegenerative Diseases (DZNE) Bonn, Bonn, Germany., Wunderlich S; Department of Neurology, Klinikum rechts der Isar School of Medicine, Technical University of Munich, Munich, Germany., Zerr I; Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.; German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany., Dichgans M; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; German Center for Cardiovascular Research (DZHK, Munich), Munich, Germany., Prüss H; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany., Endres M; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; German Center for Cardiovascular Diseases (DZHK), Partner Site Berlin, Berlin, Germany.; Center for Stroke Research Berlin (CSB), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany.

Publikováno v: Molecular psychiatry [Mol Psychiatry] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.